(2R,4R)-2-[[(4S,8R,11S)-8-methyl-11-propan-2-yl-1,5-dioxaspiro[5.5]undecan-4-yl]methyl]-3,4-dihydro-2H-pyran-4-ol | 206255-70-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2R,4R)-2-[[(4S,8R,11S)-8-methyl-11-propan-2-yl-1,5-dioxaspiro[5.5]undecan-4-yl]methyl]-3,4-dihydro-2H-pyran-4-ol
• CAS: 206255-70-1
• 化学式: C₁₉H₃₂O₄
• 分子量: 324.461
• InChiKey: IONCEUFNAFUYDD-RCSSLFFRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R,4R)-2-[[(4S,8R,11S)-8-methyl-11-propan-2-yl-1,5-dioxaspiro[5.5]undecan-4-yl]methyl]-3,4-dihydro-2H-pyran-4-ol 、 乙烯基异丁醚 在 mercury(II) diacetate 作用下， 以 十二烷 为溶剂， 反应 51.0h， 以83%的产率得到[6-(7-isopropyl-10-methyl-1,5-dioxa-spiro[5.5]undec-2-ylmethyl)-5,6-dihydro-2H-pyran-2-yl]-acetaldehyde
  参考文献：
  名称：

  The Practical Synthesis of a Novel and Highly Potent Analogue of Bryostatin

  摘要：

  Macrocycle 1 is a new highly potent analogue of bryostatin 1, a promising anti-cancer agent currently in human clinical trials. In vitro, 1 displays picomolar affinity for PKC and exhibits over 100-fold greater potency than bryostatin 1 when tested against various human cancer cell lines. Macrocycle 1 can be generated in clinically required amounts by chemical synthesis in only 19 steps (LLS) and represents a new clinical lead for the treatment of cancer.

  DOI：

  10.1021/ja027509+
• 作为产物：
  描述：

  1,3,5-pentanetriol 1,3-menthone acetal 在 (1R,2R)-(-)-[1,2-cyclohexanediamine-N,N’-bis(3,5-di-tertbutylsalicylidine)]chromium(III) chloride cerium(III) chloride 、 草酰氯 、 4 A molecular sieve 、 二甲基亚砜 作用下， 以 甲醇 、 二氯甲烷 、 丙酮 为溶剂， 反应 34.89h， 生成 (2R,4R)-2-[[(4S,8R,11S)-8-methyl-11-propan-2-yl-1,5-dioxaspiro[5.5]undecan-4-yl]methyl]-3,4-dihydro-2H-pyran-4-ol
  参考文献：
  名称：

  The Practical Synthesis of a Novel and Highly Potent Analogue of Bryostatin

  摘要：

  Macrocycle 1 is a new highly potent analogue of bryostatin 1, a promising anti-cancer agent currently in human clinical trials. In vitro, 1 displays picomolar affinity for PKC and exhibits over 100-fold greater potency than bryostatin 1 when tested against various human cancer cell lines. Macrocycle 1 can be generated in clinically required amounts by chemical synthesis in only 19 steps (LLS) and represents a new clinical lead for the treatment of cancer.

  DOI：

  10.1021/ja027509+